Prognostic Value Of ESPL1 Expressions In Human Prostate Cancer

OBJECTIVE: To investigate the expression of ESPL1 in prostate cancer,and to analyze its relationship with clinicopathological features and to explore its potential as a tumor marker for prostate cancer.Methods: The ESPL1 gene closely related to tumor prognosis was screened by downloading the gene database of Taylor database.RT-PCR and Western-Blot were used to detect the expression of ESPL1 mRNA and protein in five prostate cell lines(RWPE1,BPH,Lncap,PC3,DU145),and in human prostate tissue microarray(50prostate tissues).Immunohistochemical staining was performed on 30 benign prostate tissues,and the expression intensity of ESPL1 gene protein was quantified by immunohistochemistry.By statistical analysis of the relationship between the clinical features of prostate cancer patients and the prognosis of ESPL1 in Taylor database and TCGA database,the relationship between ESPL1 mRNA expression in prostate cancer patients and the survival time without biochemical recurrence in the Taylor database was analyzed by Cox regression model.The relationship between factors and multivariate analysis of variance.ESPL1 knockdown DU145 cell line(DU145-sh-ESPL1)and negative control cell line(DU145-NC-ESPL1)were constructed by lentiviral vector technology,and the transfection efficiency was detected by Western Blot.Finally,we constructed The cell line was subjected to cell cycle and proliferation experiments to examine the effect of ESPL1 on cell cycle and proliferation of prostate cancer cell lines.RESULTS: The expression of ESPL1 nucleic acid levels in prostate cancer tissues(n=150)and non-cancer tissues(n=29)was statistically analyzed in the Taylor database gene chip data.The results showed that ESPL1 expression was increased in prostate cancer tissues(PCa= 6.78 ± 1.86 vs Benign = 6.69 ± 1.89,p < 0.001),the difference was statistically significant.In prostate cancer cell lines,we also found that the expression of ESPL1 mRNA and protein levels was higher than that in benign prostate cell lines.Prostate tissue microarray immunohistochemistry showed that ESPL1 was highly expressed in prostate cancer tissues and low or moderate in benignprostate tissues(PCa=4.00±1.26 vs Benign=2.47±1.28,p < 0.001),the difference has statistical significane.In the Taylor database and the TCGA database,we found that the expression level of ESPL1 in prostate cancer was significantly higher than that in benign prostate tissue,and the expression level of ESPL1 and the biochemical recurrence-free survival rate of prostate cancer(p < 0.001),high Gleason score(p <0.001),advanced pathological stage(p < 0.001)and tumor without metastasis(p <0.001)were significantly associated.The results of cell cycle experiments showed that the S+G2 phase of DU145 cells was significantly decreased after ESPL1 knockdown compared with the control group.The results of the cell proliferation experiment showed that the proliferation ability of the cells in the ESPL1knockdown-expressing cell line was significantly weakened compared with the control group.Conclusions: The expression level of ESPL1 in prostate cancer is elevated and is significantly correlated with the clinical features and prognosis of prostate cancer patients.It may promote the progression of prostate cancer through cell cycle involved in cell proliferation,and has the potential to be a tumor-promoting gene as a secondary marker of prostate cancer.